This company has been acquired
La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !
LogicBio Therapeutics Résultats passés
Passé contrôle des critères 0/6
Informations clés
-18.2%
Taux de croissance des bénéfices
46.0%
Taux de croissance du BPA
Biotechs Croissance de l'industrie | 17.0% |
Taux de croissance des recettes | 77.0% |
Rendement des fonds propres | -168.7% |
Marge nette | -246.7% |
Dernière mise à jour des bénéfices | 30 Sep 2022 |
Mises à jour récentes des performances passées
Recent updates
LogicBio jumps 648% on buyout deal with AstraZeneca unit Alexion
Oct 03Bullish: Analysts Just Made A Notable Upgrade To Their LogicBio Therapeutics, Inc. (NASDAQ:LOGC) Forecasts
Aug 20LogicBio Therapeutics, Inc. (NASDAQ:LOGC) Just Reported Second-Quarter Earnings And Analysts Are Lifting Their Estimates
Aug 18LogicBio GAAP EPS of -$0.15, revenue of $3.2M
Aug 15Is LogicBio Therapeutics (NASDAQ:LOGC) Weighed On By Its Debt Load?
Jan 11Does LogicBio Therapeutics (NASDAQ:LOGC) Have A Healthy Balance Sheet?
Aug 18LogicBio EPS misses by $0.06, beats on revenue
May 10LogicBio announces agreements with CANbridge Pharma and Daiichi Sankyo
Apr 27Is LogicBio Therapeutics (NASDAQ:LOGC) Using Debt Sensibly?
Apr 12Is LogicBio Therapeutics, Inc. (NASDAQ:LOGC) Popular Amongst Insiders?
Mar 08The LogicBio Therapeutics (NASDAQ:LOGC) Share Price Has Gained 12% And Shareholders Are Hoping For More
Jan 15LogicBio extends collaboration with Children's Medical Research Institute
Jan 07LogicBio Therapeutics names new CFO
Dec 22Looking In On LogicBio
Nov 17LogicBio reports Q3 results
Nov 09Ventilation des recettes et des dépenses
Comment LogicBio Therapeutics gagne et dépense de l'argent. Sur la base des derniers bénéfices déclarés, sur une base LTM.
Historique des gains et des recettes
Date | Recettes | Les revenus | Dépenses G+A | Dépenses de R&D |
---|---|---|---|---|
30 Sep 22 | 11 | -27 | 14 | -8 |
30 Jun 22 | 10 | -31 | 15 | 0 |
31 Mar 22 | 8 | -36 | 16 | -1 |
31 Dec 21 | 5 | -40 | 16 | 0 |
30 Sep 21 | 4 | -38 | 15 | 8 |
30 Jun 21 | 3 | -36 | 14 | 1 |
31 Mar 21 | 3 | -33 | 13 | -1 |
31 Dec 20 | 3 | -33 | 12 | 0 |
30 Sep 20 | 3 | -37 | 12 | 8 |
30 Jun 20 | 2 | -40 | 11 | 17 |
31 Mar 20 | 1 | -42 | 11 | 32 |
31 Dec 19 | 0 | -40 | 10 | 31 |
30 Sep 19 | 0 | -32 | 10 | 27 |
30 Jun 19 | 0 | -29 | 10 | 21 |
31 Mar 19 | 0 | -23 | 9 | 15 |
31 Dec 18 | 0 | -18 | 7 | 11 |
30 Sep 18 | 0 | -18 | 5 | 8 |
30 Jun 18 | 0 | -11 | 4 | 6 |
31 Mar 18 | 0 | -9 | 3 | 5 |
31 Dec 17 | 0 | -8 | 2 | 4 |
Des revenus de qualité: LOGC is currently unprofitable.
Augmentation de la marge bénéficiaire: LOGC is currently unprofitable.
Analyse des flux de trésorerie disponibles par rapport aux bénéfices
Analyse de la croissance passée des bénéfices
Tendance des revenus: LOGC is unprofitable, and losses have increased over the past 5 years at a rate of 18.2% per year.
Accélération de la croissance: Unable to compare LOGC's earnings growth over the past year to its 5-year average as it is currently unprofitable
Bénéfices par rapport au secteur d'activité: LOGC is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (60.8%).
Rendement des fonds propres
ROE élevé: LOGC has a negative Return on Equity (-168.65%), as it is currently unprofitable.